Parent Page: News id: 26727 Active Page: details id: 26917


OUHSC Research News – Monday, November 6, 2023

Published: Friday, November 3, 2023

Notices and Reminders

Recently, there has been an increase in HSC personnel completing OU-Norman’s CITI training, which has led to delays in the IRB review process for research under the OUHSC IRB. OU-Norman and OUHSC are two separate organizations in CITI, with access to different training courses. For example, OU-Norman does not offer a biomedical training course and the OUHSC IRB will not accept social/behavioral research training for those conducting biomedical research.
Attached you will find OUHSC CITI Instructions for how to register and create an account. Please update and replace your materials with the correct instructions that are specific to OUHSC. Other CITI guides, information, and FAQs are available on the OUHSC IRB website, including how to add a course and how to affiliate with OUHSC.  
NIH Updates for Subaward/Consortium Written Agreements (NOT-OD-23-182)
Effective January 1, 2024, NIH will require that international subrecipients provide access to copies of all lab notebooks, all data, and all documentation that supports the research outcomes as described in the progress report to the primary recipient with a frequency of no less than once per year, in alignment with the timing requirements for Research Performance Progress Report submission. NIH will not support any agreement that does not meet the minimum requirements outlined in this notice. 
NOTE: Starting January 1st, this new requirement will be included in the Office of Research Administration’s subrecipient agreements.
For more information on these policy changes and their implications for your research, please visit the NIH subaward webpage or see answers to their FAQs

Workshops and Seminars

Harold Hamm Diabetes Center (HHDC) Research Symposium
The HHDC 20th Annual 2023 Research Symposium will be held on Friday, November 10, 2023 at the Samis Education Center in Children’s Hospital in Oklahoma City.  The Symposium will consist of selected oral presentations, poster session, and a keynote address by Mark A. Herman, MD, Associate Professor, Chief, Section of Endocrinology, Diabetes and Metabolism, E.L. Wagner, M.D., Chair of Internal Medicine II, Baylor College of Medicine. Please contact with any questions about this event.  We look forward to seeing you there!
2024 ORA/GCA Workshop - Save the Date
January 25 and 26, 2024 | Nicholson Conference Center, OKC
OUHSC faculty and staff are invited to attend a joint workshop by the Office of Research Administration (ORA) and Grants & Contracts Accounting Office (GCA).  This workshop will offer a two-day training on sponsored research topics. Additional details and agenda to come.
Questions? Please email
Fall 2023 NSF Virtual Grants Conference - Save the Date
Join the National Science Foundation (NSF) for the Fall 2023 NSF Virtual Grants Conference, to be held during the week of December 4 – 7, 2023. Registration will be free of charge and opens on Wednesday, November 8 at 12 pm ET. In the meantime, please feel free to check for the most up-to-date information and view recordings of sessions from previous conferences.
If you have any logistical questions about this virtual conference, please contact us at:     
2023 END2Cancer Conference
Date: November 30 – December 1, 2023
Description: OU Health Stephenson Cancer Center is proud to host the sixth annual in-person 2023 END2CANCER: Emerging Nanotechnology and Drug Delivery Applications for Cancer conference on Nov. 30 - Dec. 1, 2023 in Oklahoma City, Oklahoma, USA.
In its sixth year, the END2CANCER conference will start the morning of November 30, 2023 and conclude in the afternoon of December 1, 2023. The conference will bridge laboratory research conducted in the areas of nanotechnology and drug delivery to clinical application for the detection, diagnosis, imaging and treatment of cancer. The conference will host keynote, plenary and invited lectures by eminent scientists who will discuss new and emerging concepts, technologies and challenges in translating nanomedicine from bench-to-bedside. Topics to be discussed in the planned thematic sessions include Gene, mRNA, and Drug Delivery, Molecular Signaling and Targets for Therapy, Extracellular Vesicles and Tumor Signaling, Tissue Engineering and Biomimetics, Artificial Intelligence and Application in Cancer, Cancer Metabolism, and Immuno-Oncology/Immunotherapy. A special session on "Training and Career Development Grant Opportunities from the NCI" will be presented by the Director of the Center for Cancer Training at the National Cancer Institute, Dr. Oliver Bogler.  
High school, undergraduate, graduate, medical school, dental school, pharmacy, nursing, engineering students and fellows (residents, post-doctoral and clinical fellows), among others working in any area of cancer-related research are invited to register to attend and present their research work during our poster presentations and compete for awards.
The multi-disciplinary two-day conference will bring together physicians, basic scientists, engineers, physicists, chemists, post-doctoral fellows, high school and college students, patient advocates, business professionals, educators and technology transfer specialists. 
A special scientific photo session titled "Art of Science in Light of Nanomedicine" will allow participants (research staff, students and fellows) to display their best research as a photo with a catchy non-scientific caption and compete for a prize. 
Registration and Additional Information:

OUHSC Funding Opportunities

New Clinical Study Opportunities
Please note this is NOT a solicitation for study subjects
Several Pharmaceutical companies are looking for Principal Investigators to participate in the following clinical studies:
  • A Phase 4, multicenter, prospective, open-label trial describing the efficacy and safety of belimumab subcutaneous in patients with early systemic lupus erythematosus
    • Study Primary Objective:  This is a Phase 4, prospective, open-label, single arm, 3-year clinical study to describe the short-term and long-term efficacy and safety of SC belimumab in patients with early SLE that require treatment escalation despite stable initial SLE therapy
  • An Open-label, Multicenter Phase 1b Study of the Safety, Tolerability, and Pharmacokinetic / Pharmacodynamic Profile of the ATR Inhibitor M1774 in combination with DNA Damage Response Inhibitors or Immune Checkpoint Inhibitors in Participants with Metastatic or Locally Advanced Unresectable Solid Tumors.
  • A Phase 3, Randomized, Double-Blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of an Oral Factor XIa Inhibitor, after a Recent Acute Coronary Syndrome (ACS)
    • Target Population: Participants with Recent Acute Coronary Syndrome
Please contact Scott Davis at if you would like to receive more information on any of these studies. The resulting confidentiality and/or clinical study agreement will need to be routed to the Office of Research Administration.
Office of Technology Commercialization presents the following opportunity for researchers to engage with industry (click here for more information, or email or  
  • A global Fortune 500 company is seeking novel approaches that can be applied to Morbillivirus to increase the viral yield from eukaryotic cell cultures in vivo.  Approaches of interest include new methods to directly improve yield, cell culture media and cell culture media or supplements to increase/enhance yield.  Out of scope:  methods that cannot be applied to morbillivirus, propagation in non-eukaryotic cells.  Submission entails a one-page 200-300 word non-confidential brief.  Deadline 11/17.
  • Almirill, a global biopharmaceutical company focused on skin health, is seeking collaboration opportunities to understand key pathological mechanisms that can be applied to skin diseases.  Diseases of interest include: Atopic dermatitis, Hidradenitis suppurativa, Chronic uticaria, Food allergy, Vitiligo, Alopecia and non-melanoma skin cancer; mechanisms related to other diseases (i.e. asthma) that could be relevant to the above diseases are also of interest.  Applicants should complete an application form with a non-confidential overview of proposal.  Successful proposals will be awarded funding for research.  Deadline 11/17.
  • An industry leader in hair care is seeking novel technologies and insights for removal of natural and chemical color from hair to provide lightening and lift and alternatives to the chemistries currently used to create color that are safer or provide longer lasting quality.  All approaches must be considered safer, more effective or convenient or less damaging than current methods.  Submission entails a one-page 200-300 word non-confidential brief.  Deadline 11/17.
NOTE: If the project is selected to move forward with a full application, it will need to be routed through SoonerTrack.

NIH Notices 

NOTE: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted).  The letters of intent will be reviewed and a single application will be chosen for submission from the University.

NIH Funding Opportunities


Other Funding Opportunities

The Patient-Centered Outcomes Research Institute (PCORI): Virtual Applicant Town Halls for Upcoming Research Funding Opportunities
Several PCORI funding announcements (PFAs) are set to open for Letter of Intent (LOI) submission on Jan. 9, 2024, including various Topical PFAs, Broad Pragmatic Studies, implementation projects and more.  PCORI is hosting several virtual town halls starting in January to give you an overview of the organization’s mission, an in-depth look at specific funding opportunities and information you may need to submit a responsive LOI. Take advantage of this opportunity to make your next LOI submission the best it can be.  
Register today to learn more about the upcoming PCORI Funding Announcements and get answers to your most pressing questions:
American Heart Association (AHA): Submit your interest to participate in the American Heart Association’s Supporting Undergraduate Research Experiences (SURE) Program
Description: Since 2019, the American Heart Association’s (AHA) SURE program has been piloted through five U.S. academic institutions. It was borne from an AHA-commissioned study to increase the number of science, technology, engineering, mathematics, and medicine (STEMM) majors from underrepresented populations in the sciences. The program has successfully launched more than 100 undergraduate STEMM majors, and we now seek to expand the program to more institutions.
The AHA has issued a Request For Information from academic institutions in the U.S. that have the ability, infrastructure, and interest to offer robust summer research experiences to undergraduate students from underrepresented populations via providing mentors and an appropriate research environment.
View more program background and details and submit your interest here.
Deadline for information submission: Thursday, November 30, 2023
International Center for Responsible Gaming (ICRG) - Call for Proposals On Research On The Impact Of Gambling On Under-Served Communities
Description: The International Center for Responsible Gaming (ICRG) invites investigators to apply for a grant to study the impact of gambling on under-served groups and communities in the U.S. or Canada. For more information and to download the grants announcement and the Large Grant application form, visit
Application Deadline: January 22, 2024
Questions? Contact Christine Reilly, Senior Research Director (
Cystic Fibrosis Foundation (CFF) Response Requested: Soliciting input on work to better understand including people with non-CF bronchiectasis in clinical research involving people with CF
Description: This is a Request for Information (RFI) directed at obtaining input and soliciting interest in a project to identify one or more subgroups of individuals with non-CF bronchiectasis that may be similar to people with CF in their response to therapies addressing the manifestations of bronchiectasis (e.g., antimicrobial, muco-active, or anti-inflammatory therapies). Further, this work seeks to identify viable research outcome measures for therapeutic trials in bronchiectasis that would enroll people with and without CF. Use of both existing data and prospective collection of new data may be needed to fully phenotype and/or test potential outcome measures across populations. The CF Foundation is especially interested in receiving input from those familiar with research in non-CF bronchiectasis or both patient populations. Individuals or groups interested in leading this research are additionally encouraged to submit descriptions of their interest and qualifications as described below. Please consider forwarding or discussing this RFI with local experts in non-CF bronchiectasis who may not be included in the email distribution.
Additional Information and Submitting a Response: All responses must be submitted to by December 1, 2023.
Chan Zuckerberg Initiative (CZI) Request for Applications: Single-Cell Biology Data Insights Cycle 3 RFA
Description: The Chan Zuckerberg Initiative (CZI) invites applications for Cycle 3 of the Single-Cell Biology Data Insights RFA. CZI seeks to support projects that will advance the fields of single-cell biology and data science. Projects may include dedicated efforts to democratize access and usability of existing single-cell datasets, demonstrate utility by leveraging existing single-cell datasets to address impactful and challenging biological questions, and develop methods that enable greater biological insight and other major challenges brought forward.
This request for applications is the last of three currently planned cycles, with successful projects receiving 18 months of funding support. Awards are a maximum of $400,000 in total costs for Expanded Projects, and $200,000 in total costs for Focused Projects.
Application Deadline: December 5, 2023



Documents to download